Cited in
New
prognostic factors and calculators for outcome prediction in patients with
recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I
and II clinical trials. Gorlia T, Stupp R, Brandes AA, Rampling RR,
Fumoleau P, Dittrich C, Campone MM, Twelves CC, Raymond E, Hegi ME, Lacombe D,
van den Bent MJ. Eur J Cancer. 2012
May;48(8):1176-848
By using theses calculators you agree with the following License and Disclaimer
These models were developed for patients who were previously treated by
chemoradiation with temozolomide according to the results of Stupp at al.
: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K,
Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T,
Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European
Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy
Groups; National Cancer Institute of Canada Clinical Trials Group. N Engl J Med.
2005 Mar 10;352(10):987-96.
|
Calculators for PFS and OS |
|
Corticosteroids |
|
Median PFS (months)
(95% Confidence Interval) |
-
|
|
WHO Performance status |
|
PFS6 months
(%)
(95% Confidence Interval) |
-
|
|
Number of target lesions |
|
Median OS (months)
(95% Confidence Interval) |
-
|
|
Maximum diameter of the largest target lesion |
|
OS12 months
(%)
(95% Confidence Interval) |
-
|
Examples:
A patient with a performance status greater than 0 and more than one target
lesion is predicted to have a median PFS of 1.6 months (1.4-1.8) and poor chance
to be alive and free of progression at 6 months (PFS6= 2.2 % (0.2-10.2)).
Patients with good performance status (PS=0) and one target lesion have an
estimated median PFS of 3.3 months (1.9-5.5) months and PFS6 of 32.7%
(19.3-44.8) . For overall survival, patients predicted with a good prognosis
have performance status 0, no baseline steroids, one target lesion and largest
lesion has a maximum diameter equal to or lower than 42 mm. Their median OS is
18.2 month (11.4-38.9) months and OS12is 60.6% (46.0-72.3). . Patients with poor
performance status (PS2), steroids administered, more than one target lesion,
and a maximum diameter of the largest lesion greater than 42 mm are predicted
with a median OS of 2.6 months (1.9-3.9) and OS12 equal to 0% (0-0.3).
Kaplan Meier progression free and overall survival estimates for the main prognostic factors
Calibration of the prognostic models
Calibration of the pronostic models